Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04239092
Title 9-ING-41 in Pediatric Patients With Refractory Malignancies.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Actuate Therapeutics Inc.
Indications

Advanced Solid Tumor

Therapies

9-ING-41 + Irinotecan

9-ING-41

Age Groups: child | adult
Covered Countries USA


No variant requirements are available.